CA2547967A1 - Systeme pour ameliorer la detection de signaux cardiaques par des stimulateurs cardiaques, au moyen d'un traitement genetique - Google Patents

Systeme pour ameliorer la detection de signaux cardiaques par des stimulateurs cardiaques, au moyen d'un traitement genetique Download PDF

Info

Publication number: CA2547967A1
Authority: CA; Canada
Prior art keywords: genetic material; delivery; ion channel; protein; electrode
Prior art date: 1996-07-17
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002547967A

Other languages

English (en)

Inventor

Kenneth B. Stokes

Josee Morissette

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Medtronic Inc

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-07-17

Filing date

1997-04-04

Publication date

1998-01-22

1997-04-04 Application filed by Individual filed Critical Individual

1997-04-04 Priority claimed from CA002261022A external-priority patent/CA2261022C/fr

1998-01-22 Publication of CA2547967A1 publication Critical patent/CA2547967A1/fr

Status Abandoned legal-status Critical Current

Links

230000000747 cardiac effect Effects 0.000 title claims abstract description 61
230000002708 enhancing effect Effects 0.000 title abstract description 13
238000011282 treatment Methods 0.000 title description 19
230000002068 genetic effect Effects 0.000 title description 4
108090000862 Ion Channels Proteins 0.000 claims abstract description 100
102000004310 Ion Channels Human genes 0.000 claims abstract description 100
150000007523 nucleic acids Chemical class 0.000 claims abstract description 65
102000039446 nucleic acids Human genes 0.000 claims abstract description 64
108020004707 nucleic acids Proteins 0.000 claims abstract description 64
210000002064 heart cell Anatomy 0.000 claims abstract description 17
108090000623 proteins and genes Proteins 0.000 claims description 110
102000004169 proteins and genes Human genes 0.000 claims description 103
210000004027 cell Anatomy 0.000 claims description 44
239000004020 conductor Substances 0.000 claims description 10
108091006146 Channels Proteins 0.000 claims description 9
239000000463 material Substances 0.000 claims description 6
101710172814 Sodium channel protein Proteins 0.000 claims description 5
238000004891 communication Methods 0.000 claims description 5
230000000977 initiatory effect Effects 0.000 claims 5
230000014509 gene expression Effects 0.000 abstract description 17
102000018674 Sodium Channels Human genes 0.000 abstract description 16
108010052164 Sodium Channels Proteins 0.000 abstract description 16
230000001746 atrial effect Effects 0.000 description 28
238000000034 method Methods 0.000 description 20
230000002861 ventricular Effects 0.000 description 20
235000021251 pulses Nutrition 0.000 description 16
239000013598 vector Substances 0.000 description 15
239000003981 vehicle Substances 0.000 description 14
108020004414 DNA Proteins 0.000 description 13
239000002299 complementary DNA Substances 0.000 description 13
230000002107 myocardial effect Effects 0.000 description 13
150000001413 amino acids Chemical class 0.000 description 11
239000013612 plasmid Substances 0.000 description 11
230000001105 regulatory effect Effects 0.000 description 10
238000001727 in vivo Methods 0.000 description 9
239000012528 membrane Substances 0.000 description 9
210000003205 muscle Anatomy 0.000 description 9
210000004165 myocardium Anatomy 0.000 description 9
230000008488 polyadenylation Effects 0.000 description 9
239000003814 drug Substances 0.000 description 8
229940079593 drug Drugs 0.000 description 8
230000009977 dual effect Effects 0.000 description 8
238000003752 polymerase chain reaction Methods 0.000 description 8
238000001890 transfection Methods 0.000 description 8
239000002773 nucleotide Substances 0.000 description 7
125000003729 nucleotide group Chemical group 0.000 description 7
239000011734 sodium Substances 0.000 description 7
241000700605 Viruses Species 0.000 description 6
210000002837 heart atrium Anatomy 0.000 description 6
230000001965 increasing effect Effects 0.000 description 6
238000002347 injection Methods 0.000 description 6
239000007924 injection Substances 0.000 description 6
238000010361 transduction Methods 0.000 description 6
230000026683 transduction Effects 0.000 description 6
241000701161 unidentified adenovirus Species 0.000 description 6
241001430294 unidentified retrovirus Species 0.000 description 6
108091026890 Coding region Proteins 0.000 description 5
108091028043 Nucleic acid sequence Proteins 0.000 description 5
210000005003 heart tissue Anatomy 0.000 description 5
150000002500 ions Chemical class 0.000 description 5
230000028161 membrane depolarization Effects 0.000 description 5
230000007935 neutral effect Effects 0.000 description 5
230000003204 osmotic effect Effects 0.000 description 5
108090000765 processed proteins & peptides Proteins 0.000 description 5
102000004196 processed proteins & peptides Human genes 0.000 description 5
238000006467 substitution reaction Methods 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
241000124008 Mammalia Species 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
239000003416 antiarrhythmic agent Substances 0.000 description 4
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
230000001939 inductive effect Effects 0.000 description 4
239000002953 phosphate buffered saline Substances 0.000 description 4
229920001184 polypeptide Polymers 0.000 description 4
230000002441 reversible effect Effects 0.000 description 4
239000000243 solution Substances 0.000 description 4
150000003431 steroids Chemical class 0.000 description 4
238000012546 transfer Methods 0.000 description 4
239000013603 viral vector Substances 0.000 description 4
108020004705 Codon Proteins 0.000 description 3
241000702421 Dependoparvovirus Species 0.000 description 3
239000002253 acid Substances 0.000 description 3
125000003275 alpha amino acid group Chemical group 0.000 description 3
125000000539 amino acid group Chemical group 0.000 description 3
230000008901 benefit Effects 0.000 description 3
230000002950 deficient Effects 0.000 description 3
239000003623 enhancer Substances 0.000 description 3
239000012530 fluid Substances 0.000 description 3
-1 for example Substances 0.000 description 3
230000006872 improvement Effects 0.000 description 3
238000010348 incorporation Methods 0.000 description 3
239000011810 insulating material Substances 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
238000010369 molecular cloning Methods 0.000 description 3
230000035772 mutation Effects 0.000 description 3
239000002245 particle Substances 0.000 description 3
230000010412 perfusion Effects 0.000 description 3
239000008194 pharmaceutical composition Substances 0.000 description 3
238000000746 purification Methods 0.000 description 3
238000000718 qrs complex Methods 0.000 description 3
230000010076 replication Effects 0.000 description 3
108091008146 restriction endonucleases Proteins 0.000 description 3
230000001360 synchronised effect Effects 0.000 description 3
230000003612 virological effect Effects 0.000 description 3
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
241000701022 Cytomegalovirus Species 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
108010042407 Endonucleases Proteins 0.000 description 2
102000004533 Endonucleases Human genes 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
241000725303 Human immunodeficiency virus Species 0.000 description 2
102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 2
108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
108091005461 Nucleic proteins Proteins 0.000 description 2
238000009004 PCR Kit Methods 0.000 description 2
108010029485 Protein Isoforms Proteins 0.000 description 2
102000001708 Protein Isoforms Human genes 0.000 description 2
102100026827 Protein associated with UVRAG as autophagy enhancer Human genes 0.000 description 2
101710102978 Protein associated with UVRAG as autophagy enhancer Proteins 0.000 description 2
108091034057 RNA (poly(A)) Proteins 0.000 description 2
241000700159 Rattus Species 0.000 description 2
241000714474 Rous sarcoma virus Species 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
230000036982 action potential Effects 0.000 description 2
238000007792 addition Methods 0.000 description 2
125000003118 aryl group Chemical group 0.000 description 2
210000001124 body fluid Anatomy 0.000 description 2
239000010839 body fluid Substances 0.000 description 2
210000005242 cardiac chamber Anatomy 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
230000008602 contraction Effects 0.000 description 2
CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
238000012217 deletion Methods 0.000 description 2
230000037430 deletion Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
229960002344 dexamethasone sodium phosphate Drugs 0.000 description 2
PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
238000010586 diagram Methods 0.000 description 2
230000000694 effects Effects 0.000 description 2
239000013604 expression vector Substances 0.000 description 2
238000007667 floating Methods 0.000 description 2
239000012634 fragment Substances 0.000 description 2
238000001415 gene therapy Methods 0.000 description 2
210000005260 human cell Anatomy 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
238000001802 infusion Methods 0.000 description 2
239000002502 liposome Substances 0.000 description 2
210000004962 mammalian cell Anatomy 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
210000002569 neuron Anatomy 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
238000004806 packaging method and process Methods 0.000 description 2
239000013600 plasmid vector Substances 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
230000001177 retroviral effect Effects 0.000 description 2
238000010839 reverse transcription Methods 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
230000002269 spontaneous effect Effects 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
VLPIATFUUWWMKC-SNVBAGLBSA-N (2r)-1-(2,6-dimethylphenoxy)propan-2-amine Chemical compound C[C@@H](N)COC1=C(C)C=CC=C1C VLPIATFUUWWMKC-SNVBAGLBSA-N 0.000 description 1
SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
102000055025 Adenosine deaminases Human genes 0.000 description 1
241000024188 Andala Species 0.000 description 1
206010003671 Atrioventricular Block Diseases 0.000 description 1
241000972773 Aulopiformes Species 0.000 description 1
208000020446 Cardiac disease Diseases 0.000 description 1
102000034573 Channels Human genes 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
238000001712 DNA sequencing Methods 0.000 description 1
206010011878 Deafness Diseases 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
208000010271 Heart Block Diseases 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
102000001554 Hemoglobins Human genes 0.000 description 1
108010054147 Hemoglobins Proteins 0.000 description 1
108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
108090000362 Lymphotoxin-beta Proteins 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
102000003792 Metallothionein Human genes 0.000 description 1
108090000157 Metallothionein Proteins 0.000 description 1
241000713333 Mouse mammary tumor virus Species 0.000 description 1
108010086093 Mung Bean Nuclease Proteins 0.000 description 1
102000003505 Myosin Human genes 0.000 description 1
108060008487 Myosin Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
102000013009 Pyruvate Kinase Human genes 0.000 description 1
108020005115 Pyruvate Kinase Proteins 0.000 description 1
108700008625 Reporter Genes Proteins 0.000 description 1
241000710961 Semliki Forest virus Species 0.000 description 1
206010040639 Sick sinus syndrome Diseases 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
241000282887 Suidae Species 0.000 description 1
206010042566 Superinfection Diseases 0.000 description 1
239000004809 Teflon Substances 0.000 description 1
229920006362 Teflon® Polymers 0.000 description 1
102000006601 Thymidine Kinase Human genes 0.000 description 1
108020004440 Thymidine kinase Proteins 0.000 description 1
102000013534 Troponin C Human genes 0.000 description 1
241000700618 Vaccinia virus Species 0.000 description 1
108020000999 Viral RNA Proteins 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
230000003321 amplification Effects 0.000 description 1
238000004873 anchoring Methods 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
239000012867 bioactive agent Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
210000000748 cardiovascular system Anatomy 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
108091092356 cellular DNA Proteins 0.000 description 1
108091092328 cellular RNA Proteins 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
238000010367 cloning Methods 0.000 description 1
238000000975 co-precipitation Methods 0.000 description 1
239000000470 constituent Substances 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000012937 correction Methods 0.000 description 1
229960003624 creatine Drugs 0.000 description 1
239000006046 creatine Substances 0.000 description 1
238000013461 design Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
241001493065 dsRNA viruses Species 0.000 description 1
238000002565 electrocardiography Methods 0.000 description 1
239000007772 electrode material Substances 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
108010052305 exodeoxyribonuclease III Proteins 0.000 description 1
239000013613 expression plasmid Substances 0.000 description 1
238000000605 extraction Methods 0.000 description 1
230000004927 fusion Effects 0.000 description 1
238000007429 general method Methods 0.000 description 1
210000004524 haematopoietic cell Anatomy 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
238000002513 implantation Methods 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
230000010354 integration Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
238000011866 long-term treatment Methods 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
229910021645 metal ion Inorganic materials 0.000 description 1
229960003404 mexiletine Drugs 0.000 description 1
230000000869 mutational effect Effects 0.000 description 1
239000002105 nanoparticle Substances 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
229920002635 polyurethane Polymers 0.000 description 1
239000004814 polyurethane Substances 0.000 description 1
230000001566 pro-viral effect Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
230000004213 regulation of atrial cardiomyocyte membrane depolarization Effects 0.000 description 1
230000034225 regulation of ventricular cardiomyocyte membrane depolarization Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
235000019515 salmon Nutrition 0.000 description 1
239000000523 sample Substances 0.000 description 1
239000003566 sealing material Substances 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000002195 soluble material Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
241000894007 species Species 0.000 description 1
239000000126 substance Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
239000003104 tissue culture media Substances 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
230000014616 translation Effects 0.000 description 1
108091005703 transmembrane proteins Proteins 0.000 description 1
102000035160 transmembrane proteins Human genes 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
229960001722 verapamil Drugs 0.000 description 1

Landscapes

Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CA002547967A 1996-07-17 1997-04-04 Systeme pour ameliorer la detection de signaux cardiaques par des stimulateurs cardiaques, au moyen d'un traitement genetique Abandoned CA2547967A1 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US68243396A	1996-07-17	1996-07-17
US08/682,433		1996-07-17
CA002261022A CA2261022C (fr)	1996-07-17	1997-04-04	Systeme pour ameliorer la detection de signaux cardiaques par des stimulateurs cardiaques, au moyen d'un traitement genetique

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002261022A Division CA2261022C (fr)	1996-07-17	1997-04-04	Systeme pour ameliorer la detection de signaux cardiaques par des stimulateurs cardiaques, au moyen d'un traitement genetique

Publications (1)

Publication Number	Publication Date
CA2547967A1 true CA2547967A1 (fr)	1998-01-22

Family

ID=37441493

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002547967A Abandoned CA2547967A1 (fr)	1996-07-17	1997-04-04	Systeme pour ameliorer la detection de signaux cardiaques par des stimulateurs cardiaques, au moyen d'un traitement genetique

Country Status (1)

Country	Link
CA (1)	CA2547967A1 (fr)

1997
- 1997-04-04 CA CA002547967A patent/CA2547967A1/fr not_active Abandoned

Publication	Publication Date	Title
US7337011B2 (en)	2008-02-26	System and method for enhancing cardiac signal sensing by cardiac pacemakers through genetic treatment
US7731653B2 (en)	2010-06-08	System and method for genetically treating cardiac conduction disturbances
EP1620132B1 (fr)	2011-08-03	Regulateur cardiaque biologique
EP1239776B1 (fr)	2007-02-28	Aiguille hypodermique munie d'une pointe poreuse
US7245973B2 (en)	2007-07-17	His bundle mapping, pacing, and injection lead
US20080081354A1 (en)	2008-04-03	Devices, vectors and methods for inducible ischemia cardioprotection
US7778705B2 (en)	2010-08-17	Electronic and biological pacemaker systems
US9096685B2 (en)	2015-08-04	Genetic modification of targeted regions of the cardiac conduction system
US20040236377A1 (en)	2004-11-25	System and method for enhancing cardiac signal sensing by cardiac pacemakers through genetic treatment
CA2261022C (fr)	2006-09-05	Systeme pour ameliorer la detection de signaux cardiaques par des stimulateurs cardiaques, au moyen d'un traitement genetique
CA2260756C (fr)	2007-07-10	Systeme pour traiter genetiquement les anomalies de conduction cardiaque
CA2547967A1 (fr)	1998-01-22	Systeme pour ameliorer la detection de signaux cardiaques par des stimulateurs cardiaques, au moyen d'un traitement genetique

Legal Events

Date	Code	Title	Description
2006-06-13	EEER	Examination request
2009-04-06	FZDE	Dead